Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis

Neeraj Gupta,Michael J Hanley,R Donald Harvey,Ashraf Z Badros,Brea C Lipe,Vishal Kukreti,Jesus G Berdeja,Huyuan Yang,Ai-Min Hui,Xiaoquan Zhang,Karthik Venkatakrishnan,Ajai Chari

doi:10.1182/blood.v126.23.4227.4227

Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis

Neeraj Gupta, Michael J Hanley + Show 10 more

https://doi.org/10.1182/blood.v126.23.4227.4227

Copy DOI

Journal: Blood	Publication Date: Dec 3, 2015
Citations: 2

Affiliation: Takeda (United States), Millennium Engineering and Integration (United States), Emory University, University of Maryland, Baltimore, University of Kansas, University Health Network, Mount Sinai Medical Center

#End-Stage Renal Disease Groups #Oral Proteasome Inhibitor Ixazomib + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis

Full Text